BioSpace News Archive

Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients

38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8th at 12:30 pm ET being held in Boston, Massachusetts.

Neovasc Inc. announced publication of the manuscript, “Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study” in the International Journal of Cardiology

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.

Mallinckrodt to fund up to $10 million in collaborative research programs over five years to focus on rare diseases

Eiger BioPharmaceuticals, Inc. announced first patient enrolled in the Phase 2 LIFT Study conducted within the National Institutes of Health (NIH) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Immix Biopharma, Inc. announced that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110.

Substantial Reduction in CytRx Cash Burn Rate This Quarter

Cure Genetics Co., Ltd announced the closing of $17 million Series A financing, led by Qiming Venture Partners.

FDA has confirmed HPPI’s clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission